Skip to main content
  • English
  • Català
  • Español
Home
  • Company
    • Overview & History
    • Team
    • Join Oryzon
  • Epigenetics
    • Histone Code Hypothesis
    • Modulator Enzymes
    • LSD1 & Disease
    • Technology Platforms
    • Scientific Publications by Oryzon
  • Therapeutic Programs
    • Strategy
    • LSD1 & Cancer
    • Oryzon's Pipeline
  • Collaborative Research
    • Collaborative Projects
  • For Patient
    • Patient Information
  • Shareholders and Investors
    • Investor Information and News
    • Share Information
    • Events & Presentations
    • Financial Information & Downloads
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Press Releases
  • Contact
    • General Contact
    • Investor Contact
    • Email Alerts

News

Archive

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

News & Press Releases

2 May 2013
Oryzon to Present its LSD1 programs in Acute Leukemias and in Neurodegenerative disorders at the GTC’s 3rd Epigenetics in Drug Discovery conference in Boston
10 September 2012
ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia
13 June 2012
Oryzon assigns Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs
25 May 2012
Oryzon nominates specific LSD1 inhibitor as drug candidate to enter preclinical development in Acute leukemia and other hematological cancers
8 May 2012
Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
11 April 2012
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
19 March 2012
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
20 February 2012
Oryzon participates in a R&D European consortium in Parkinson’s disease
6 February 2012
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
26 January 2012
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6

Pages

  • « first
  • ‹ previous
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • next ›
  • last »

epigen-logo

Epigenetic drugs for a better world.

United States

Oryzon Corporate
245 First Street, Suite 1800
Cambridge, MA 02142

T: (617) 444-8786
F: (617) 444- 8405
info@oryzon.com

Spain

Oryzon Genomics
Sant Ferran 74
08940 Cornellà de Llobregat, Barcelona, Spain

T: (+34) 93 515 1313
F: (+34) 93 377 4028
info@oryzon.com

Legal Advice
Privacy Policy

Investor Information

ISIN: ES0167733015 - ORY

Please contact us for investor information.

Contact Us

© 2019

Oryzon Genomics

All Rights Reserved

  • Legal Advice
  • Privacy Policy
  • Registered address: Carrera de San Jerónimo 15, 2ª planta, 28014 Madrid (Spain)